Cargando…

OC.10.2 A SERUM METABOLOMICS ANALYSIS TO UNDERSTAND THE INTERPLAY BETWEEN BIOLOGICAL THERAPIES IN IBD PATIENTS AND SUSCEPTIBILITY TO SARS-COV-2 INFECTION

Detalles Bibliográficos
Autores principales:	Pisani, L.F., Mola, S., Crespi, G., Caprioli, F., Annunaziata, M., Manfredi, M., Pastorelli, L., Porta, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. 2022
Materias:	Oral Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065936/ http://dx.doi.org/10.1016/S1590-8658(22)00327-9

Ejemplares similares

OC.02.2 REDUCED EXPRESSION OF SARS-COV-2 INFECTION-RELATED GENES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Pisani, L.F., et al.
Publicado: (2022)

OC.02.1 SAFETY OF COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA OF A NATIONAL STUDY (ESCAPE-IBD)
por: Todeschini, A., et al.
Publicado: (2022)

OC.06.8 THE EMERGING ROLE OF TELEMEDICINE IN GASTROENTEROLOGY DURING THE COVID-19 PANDEMIC: A STUDY ON ITS FEASIBILITY AND PATIENTS’ TRUST
por: Costantino, A., et al.
Publicado: (2021)

IT inventory and resource management with OCS inventory NG 1.02
por: Antal, Barzan
Publicado: (2010)

OC.05.6 HELICOBACTER PYLORI AND SARS-COV-2: A DANGEROUS PATHOGENETIC CORRELATION?
por: Termite, F., et al.
Publicado: (2023)

OC.15.2 HUMORAL RESPONSE TO 2-DOSE BNT162B2 MRNA VACCINE FOR COVID-19 IN LIVER TRANSPLANT RECIPIENTS
por: Guarino, M., et al.
Publicado: (2022)

OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY
por: Macaluso, F.S., et al.
Publicado: (2023)

OC.14.1 SARS-COV-2 INFECTION DOES NOT WORSEN THE COURSE OF INFLAMMATORY BOWEL DISEASE IN THE LONG TERM
por: Neri, B., et al.
Publicado: (2023)

OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME
por: Marasco, G., et al.
Publicado: (2023)

OC.07.4 RAFOXANIDE INDUCES IMMUNOGENIC DEATH OF COLORECTAL CANCER CELLS
por: Di Grazia, A., et al.
Publicado: (2021)

S10.2d Fungal beta-glucans and mannan performances in HIV-associated histoplasmosis
por: Moussiegt, Aurore, et al.
Publicado: (2022)

OC.02.9 IMPACT OF COVID-19 OUTBREAK ON GASTRO-INTESTINAL CANCER BURDEN
por: Milluzzo, S.M., et al.
Publicado: (2021)

OC.06.9 ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUS IN A COHORT OF PATIENTS WITH CROHN’S DISEASE
por: Nardone, O.M., et al.
Publicado: (2021)

OC.07.2 FUNCTIONAL GASTROINTESTINAL AND SOMATOFORM SYMPTOMS FIVE MONTHS AFTER SARS-COV-2 INFECTION: A CONTROLLED COHORT STUDY
por: Noviello, D., et al.
Publicado: (2021)

OC.08.1 THE IMPACT OF THE COVID-19 PANDEMIC ON HOSPITALIZATIONS FOR DIVERTICULAR DISEASE
por: Germana’, B., et al.
Publicado: (2022)

OC.04.1 HIGH LEVELS OF TRANSAMINASES AT ADMISSION PREDICT A SEVERE DISEASE COURSE IN COVID-19 HOSPITALIZED PATIENTS
por: Pelizzaro, F., et al.
Publicado: (2021)

P102 Nuclear magnetic resonance -based identification of metabolites in dermatophytes
por: Das, Anupam, et al.
Publicado: (2022)

Su102 DIFFERENCES IN INTESTINAL EPITHELIAL GENE EXPRESSION MODULATES SARS-COV-2 INFECTION IN HUMAN IBD ENTEROIDS
por: Alvarado, David M., et al.
Publicado: (2021)

OC-02 Khorana risk score at diagnosis of SARS-CoV-2 infection as a predicting tool for venous thromboembolic disease development, and overall mortality, in cancer patients
por: López Jiménez, C., et al.
Publicado: (2021)

OC.04.8 IMPACT OF COVID-19 PANDEMIC ON REFERRAL OF PATIENTS WITH LIVER DISEASE TO A LIVER TRANSPLANT CENTER
por: Germani, G., et al.
Publicado: (2021)

102. A Retrospective Case Series of West Nile Neuroinvasive Disease in Two Tertiary Health Centers in Miami
por: Cordova, Leopoldo, et al.
Publicado: (2021)

S102: OBLIGATE N-TERMINAL BUT NOT C-TERMINAL MONOFERRIC TRANSFERRIN AMELIORATES ANEMIA IN β-THALASSEMIC MICE
por: Guerra, A., et al.
Publicado: (2022)

OC.06.7 LOWER INCIDENCE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH NON-GUT SELECTIVE BIOLOGIC THERAPY
por: Ferretti, F., et al.
Publicado: (2021)

OC.01.3 NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING HOSPITALIZATION DURING THE FIRST PHASE OF THE COVID-19 PANDEMIC IN VENETO REGION
por: Germana”, B., et al.
Publicado: (2021)

S10.3d Yeast Microbiome in patients with inflammatory bowel disease (IBD)
por: Vaezi, Afsane, et al.
Publicado: (2022)

OC-01 Venous thromboembolic events during the first and second waves of Covid-19 in breast cancer patients treated in an outpatient day hospital
por: Illarramendi, J., et al.
Publicado: (2021)

Maternal mortality and its relationship to Emergency Obstetric Care (EmOC) in a tertiary care hospital in South India
por: Dasari, Papa
Publicado: (2014)

Trust in telemedicine from IBD outpatients during the COVID-19 pandemic
por: Costantino, A., et al.
Publicado: (2021)

OC-03 Heparin treatment in COVID-19 patients is associated with reduced in-hospital mortality: findings from an observational multicenter study in Italy and a meta-analysis of 11 studies
por: Costanzo, S., et al.
Publicado: (2021)

OC.11.4 ITALIAN SOCIETY FOR DIGESTIVE DISEASES ACCREDITATION PROGRAM DURING COVID-19 PANDEMIC: RESULTS IN REMOTE REACCREDITATION IN 15 CENTRES
por: Spinzi, G., et al.
Publicado: (2023)

Nutritional genomics and metabolomics in obesity and type 2 diabetes
por: Hu, Frank B, et al.
Publicado: (2014)

The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD
por: Tavakoli, Paris, et al.
Publicado: (2022)

The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance
por: Mola, Silvia, et al.
Publicado: (2020)

Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
por: Pesonen, Sari, et al.
Publicado: (2015)

New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD
por: Larabi, Anaïs, et al.
Publicado: (2019)

AF.49 DETERMINANTS OF COVID-19 VACCINE HESITANCY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): RESULTS OF A NATIONAL SURVEY OF THE ITALIAN IBD PATIENTS’ ASSOCIATION (AMICI ONLUS)
por: Costantino, A., et al.
Publicado: (2021)

EuCARD-2 Progress Report WP10.2
por: Bottura, L, et al.
Publicado: (2015)

A4 PREDNISOLONE, A GLUCOCORTICOID WIDELY USED FOR TREATMENT OF IBD, ENHANCES A HUMAN INTERLEUKIN-4-ACTIVATED MACROPHAGE PHENOTYPE
por: Deshpande, R S, et al.
Publicado: (2023)

Impact of COVID-19 Outbreak on the Management of Patients With Severe IBD: A Domino Effect
por: Occhipinti, Vincenzo, et al.
Publicado: (2021)

44. Impact of Nursing Home (NH) Universal Decolonization and COVID Prevention Training on COVID-19 Burden During the 2020-2021 Winter Surge in Orange County (OC), California (CA)
por: Gussin, Gabrielle, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gcld6tancoa2bs5e77f2pjltp8